论文部分内容阅读
目的探讨急性ST段抬高型心梗并心源性休克应用瑞替普酶溶栓疗效。方法选择我院2006年01月~2014年1月ST段抬高型心梗并心源性休克患者62例，实验组(A组)36例给予瑞替普酶溶栓治疗，对照组(B组)26例给予尿激酶溶栓治疗。所有患者均为溶栓适应症。本地区未开展急诊介入治疗，转运PCI路程>120min，征求患者家属意见，采取就地溶栓治疗。结果A组36例患者，在本院死亡9例，转院途中死亡员例，总体死亡率27.7豫；B组26例患者，在本院死亡16例，转院2例，途中死亡1例，总体死亡率65.3豫；两组死亡率有统计学差异。结论瑞替普酶溶栓治疗急性ST段抬高型心梗并心源性休克，可明显降低死亡率，并改善预后，疗效明显优于第一代溶栓药。方法简单有效，且效价比极高。“,”Objective To investigate the ef icacy of reteplase thrombolytic for acute ST-segment elevation myocardial infarction complicated cardiogenic shock .Methods We selected 62 patients with acute ST-segment elevation myocardial infarction complicated cardiogenic shock In our hospital from January 2006 to January 2014. Al patient divided into two groups. there are 36 patients were given reteplase thrombolytic therapy in experimental group (group A) , and the other 26 patients received urokinase thrombolytic therapy in control group ( group B). Al patients were suited for thrombolysis. As the emergency intervention undeveloped in region,and PCI transit time more than 120 minutes, so these patients were taken thrombolytic therapy After seeking views of patients family member.Results In Group A, there are 9 cases died in the hospital , transfer ed 1 case died on the way , the overal mortality rate is 27.7% ;In group B, there are 16 patients died in the hospital, transfer ed 2 cases ,one case died on the way , the overal mortality rate is 53.8%; There are significant statistical y dif erence in mortality ( <0.05). Conclusion Reteplase thrombolytic therapy for acute ST-segment elevation myocardial infarction complicated cardiogenic shock, can significantly reduce mortality and . improve the prognosis .The ef icacy bet er than the first generation thrombolytic drugs . The treatment is simple and ef ective, and ef icient price.